RE:The way forward -jmm1228 wrote: Options keep the best people in the lineup. PP are a vital source of funds at critical stages however it is likely that recent successes have resulted
in some major suitor interest and discussions and they would frown on such..
There are level heads in command of superb breakthrough technology - the noise from the bleachers may reach their ears but they have all the facts and will get TLT airborne when they know liftoff speed has been reached.
Thankfully we have some great input here which is helpful while the rapids of development are navigated - sadly some posters just don’t get it.
Price will come as everything falls into place and that is finally beginning to happen.
Now is the time to be onboard!
With all respect jmm1228 but I think this board needs something more substantial then another rah rah post if it hopes to attract investors willing to pay more for the shares. Cheerleading doesn't win the game in the healthcare field when it seems like everyone is working on a cure for something. I don't expect you to solve the problem of what ails TLT's sp. There are poster-shareholders here that have been following the stock for now onto 6 years and they still haven't worked out the kinks yet. This board has become much too forward looking lazy at the expense of having an open discussion on why the sp is not following what seems to be good results from the phase 1b trial. If sit and be passive were a virtue contest some folks here would win hands down. We can't keep blaming it on the Venture Exchange when there are pot stocks like Organigram doing well on that exchange. IMO, there's something fundamently lacking in the way this company promotes itself but how does one solve that issue when every other biotech firm is shouting for attention also? How you separate yourself from the crowd is what the new CEO needs to figure out. I hope he isn't content to follow the ways of the past.